Get the Stockscreener App
33.12
2.03%
0.66
Xoma Royalty Corp stock is traded at $33.12, with a volume of 43,850.
It is up +2.03% in the last 24 hours and up +29.98% over the past month.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.
See More
Previous Close:
$32.46
Open:
$32.23
24h Volume:
43,850
Relative Volume:
0.76
Market Cap:
$400.35M
Revenue:
$9.71M
Net Income/Loss:
$-29.96M
P/E Ratio:
-9.5172
EPS:
-3.48
Net Cash Flow:
$-14.79M
1W Performance:
+4.84%
1M Performance:
+29.98%
6M Performance:
+40.82%
1Y Performance:
+14.25%
1-Day Range:
$32.01
$33.75
1-Week Range:
$30.55
$33.75
52-Week Range:
$18.35
$35.00
Xoma Royalty Corp Stock (XOMA) Company Profile
Name
Xoma Royalty Corp
Sector
Industry
Phone
510-204-7239
Address
2200 POWELL STREET, EMERYVILLE, CA
Compare XOMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XOMA
Xoma Royalty Corp
|
33.12 | 383.66M | 9.71M | -29.96M | -14.79M | -3.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.94 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
600.67 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
463.88 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
664.22 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.18 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Xoma Royalty Corp Stock (XOMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-25 | Initiated | The Benchmark Company | Buy |
| Apr-29-24 | Initiated | Leerink Partners | Outperform |
| Sep-07-21 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-29-21 | Initiated | Aegis Capital | Buy |
| Jan-19-21 | Reiterated | H.C. Wainwright | Buy |
| Jan-18-18 | Reiterated | H.C. Wainwright | Buy |
| Oct-17-17 | Resumed | H.C. Wainwright | Buy |
| Sep-05-17 | Upgrade | Wedbush | Neutral → Outperform |
| Jun-12-17 | Initiated | H.C. Wainwright | Buy |
| Nov-14-16 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-11-16 | Reiterated | Wedbush | Outperform |
| Jul-23-15 | Downgrade | Jefferies | Buy → Hold |
| Jul-22-15 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jul-22-15 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Oct-10-14 | Resumed | ROTH Capital | Buy |
| Apr-29-14 | Upgrade | MLV & Co | Hold → Buy |
| Mar-11-14 | Downgrade | MLV & Co | Buy → Hold |
| Mar-05-14 | Reiterated | Ladenburg Thalmann | Buy |
| Oct-31-13 | Reiterated | MLV & Co | Buy |
| May-09-13 | Reiterated | Ladenburg Thalmann | Buy |
| May-14-12 | Initiated | Cowen & Co | Outperform |
| Mar-31-11 | Reiterated | MLV Capital | Buy |
| Mar-23-11 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-06-11 | Reiterated | Ladenburg Thalmann | Buy |
| Jan-04-11 | Reiterated | Wedbush | Outperform |
View All
Xoma Royalty Corp Stock (XOMA) Latest News
Mural Jumps on Partnership with XOMA - Baystreet.ca
Xoma, a drug royalty specialist, buys another ‘zombie’ biotech - BioPharma Dive
Heatmap analysis for XOMA Royalty Corporation and competitorsJuly 2025 Summary & Reliable Volume Spike Alerts - Newser
Mural Oncology to be Acquired by XRA 5 - citybiz
Mural Oncology plc enters acquisition agreement with XRA 5 Corp (XOMA Royalty Corporation) - Arthur Cox LLP
Xoma adds fading Mural Oncology to portfolio of struggling biotechs - Fierce Biotech
XOMA Royalty To Acquire Mural Oncology - Nasdaq
XOMA Royalty Unit to Acquire Mural Oncology - MarketScreener
XOMA Royalty to acquire Mural Oncology for up to $2.24 per share - Investing.com
Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share - Yahoo Finance
WALTHAM, DUBLIN, EMERYVILLEMural Oncology agrees to acquisition by XOMA Royalty subsidiary - Investing.com
98% Premium: XOMA Royalty Acquires Cancer Drug Developer Mural Oncology in $36.2M Strategic Deal - Stock Titan
Analyzing drawdowns of XOMA Royalty Corporation with statistical toolsMarket Growth Review & Weekly Watchlist for Hot Stocks - Newser
Using Bollinger Bands to evaluate XOMA Royalty CorporationShort Setup & AI Enhanced Trade Execution Alerts - Newser
What Fibonacci levels say about XOMA Royalty Corporation reboundQuarterly Market Review & Trade Opportunity Analysis - Newser
What’s next for XOMA Royalty Corporation stock price2025 Big Picture & Free Daily Entry Point Trade Alerts - Newser
Analyzing recovery setups for XOMA Royalty Corporation investorsQuarterly Portfolio Report & Real-Time Buy Zone Alerts - Newser
XOMA Royalty Corporation stock retracement – recovery analysisPortfolio Growth Summary & Weekly Top Gainers Trade List - Newser
Can a trend reversal in XOMA Royalty Corporation lead to recoveryJuly 2025 Fed Impact & Real-Time Chart Pattern Alerts - Newser
How Much Upside is Left in XOMA Royalty (XOMA)? Wall Street Analysts Think 106.15% - Yahoo Finance
Q3 EPS Estimates for XOMA Royalty Reduced by Leerink Partnrs - Defense World
What institutional flow reveals about XOMA Royalty CorporationWeekly Profit Report & Community Verified Trade Signals - Newser
XOMA Co. (NASDAQ:XOMAP) Short Interest Update - Defense World
Is XOMA Royalty Corporation stock a buy or sellTrade Entry Summary & Precise Trade Entry Recommendations - thegnnews.com
Leerink Partnrs Forecasts Higher Earnings for XOMA Royalty - Defense World
Custom watchlist performance reports with XOMA Royalty Corporation2025 Risk Factors & Expert Approved Trade Ideas - Newser
What the charts say about XOMA Royalty Corporation today2025 AllTime Highs & Consistent Return Strategy Ideas - Newser
Xoma Completes Merger with Turnstone Biologics Corp - TipRanks
Xoma Corp. Reports Strong Earnings Growth in 2025 - MSN
Xoma: Leerink Partners Reaffirms Buy Rating with $55 Target, Analyst Consensus at Moderate Buy with $62 Average Target - AInvest
We Think XOMA Royalty (NASDAQ:XOMA) Has A Fair Chunk Of Debt - 富途牛牛
Deal Watch: Lilly Teams With GPCR-Focused Superluminal In Cardiometabolic Disease - insights.citeline.com
XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements - MarketScreener
Leerink Partners reiterates Outperform rating on XOMA stock amid strong Q2 results - Investing.com Nigeria
XOMA (NASDAQ:XOMAO) Trading Up 0.4% – Here’s Why - Defense World
XOMA Royalty 2025 Q2 Earnings Declining Net Income Amid Revenue Growth - AInvest
Live market analysis of XOMA Royalty CorporationWeekly Risk Summary & Free Daily Entry Point Trade Alerts - Newser
XOMA Royalty Corp Surpasses Revenue Estimates with $13.1M Q2 Revenue, EPS Misses Expectations - AInvest
LAVA Reports Second Quarter 2025 Financial Results and Provides Corporate Update - uk.finance.yahoo.com
XOMA Posts 39% Revenue Growth in Q2, Net Income Down 42.5% - AInvest
XOMA Royalty (XOMA) Q2 Earnings and Revenues Surpass Estimates - Yahoo Finance
XOMA Royalty Corp reports results for the quarter ended June 30Earnings Summary - TradingView
Will breakout in XOMA Royalty Corporation lead to full recoveryQuarterly Market Review & Weekly Return Optimization Plans - Newser
XOMA Royalty: A Biotech Royalty Aggregator with Explosive Growth Potential - AInvest
XOMA Royalty Corporation Reports Q2 2025 Financial Results - TradingView
XOMA Royalty Corp SEC 10-Q Report - TradingView
Lava Therapeutics shares rise 1.32% intraday after XOMA Royalty Corporation's acquisition of Turnstone Biologics Corp. - AInvest
Should you wait for a breakout in XOMA Royalty CorporationBuy Zone Strategy with Pattern Recognition - Newser
Evaluating XOMA Royalty Corporation with trendline analysisFree Conservative Entry for High Return Setup - Newser
Gold Royalty Corp. shares fall 3.25% intraday after Royalty Management Holding Corporation reported record second quarterly results for the period ended June 30, 2025. - AInvest
XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics - GlobeNewswire
Xoma Royalty Corp Stock (XOMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Xoma Royalty Corp Stock (XOMA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hughes Owen | Chief Executive Officer |
May 19 '25 |
Option Exercise |
0.00 |
53,359 |
0 |
88,338 |
| Hughes Owen | Chief Executive Officer |
May 20 '25 |
Sale |
25.38 |
25,637 |
650,667 |
62,701 |
| BURNS THOMAS M. | SVP, Finance & CFO |
May 19 '25 |
Option Exercise |
0.00 |
17,773 |
0 |
33,045 |
| BURNS THOMAS M. | SVP, Finance & CFO |
May 20 '25 |
Sale |
25.38 |
10,482 |
266,033 |
22,563 |
| BVF PARTNERS L P/IL | 10% Owner |
May 16 '25 |
Sale |
27.10 |
392,723 |
10,642,793 |
1,267,545 |
| Sitko Bradley | Chief Investment Officer |
Apr 07 '25 |
Buy |
24.70 |
2,000 |
49,400 |
5,045 |
| LIMBER JOSEPH M | Director |
Apr 03 '25 |
Buy |
25.24 |
17,935 |
452,631 |
16,524 |
| LIMBER JOSEPH M | Director |
Apr 04 '25 |
Buy |
25.40 |
6,822 |
173,293 |
20,000 |
| LIMBER JOSEPH M | Director |
Apr 07 '25 |
Buy |
25.60 |
5,243 |
134,221 |
10,000 |
| Sitko Bradley | Chief Investment Officer |
Mar 31 '25 |
Buy |
21.04 |
1,245 |
26,201 |
11,484 |
0.94%
0.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):